Owners, management and financials
CVR: 45364577
DKK 1,026,737
Revenue
Net result: DKK -1,626,789
Walden Holding ApS (50-66,65%), Sophie Holding ApS (10-14,99%)
1 more
CVR · view owners
Helena Safavi-Hemami, Walden Emil Bjørn-Yoshimoto
CVR · view management
Active
Founded 29 January 2025
CVR · view overview
4 employees
CVR · 2026
Owner registered: Sophie Holding ApS
CVR · 17/10/2025
View the full event history
Akasi Pharma ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2025. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Helena Safavi-Hemami and Walden Emil Bjørn-Yoshimoto. The company is owned by Walden Holding ApS, Sophie Holding ApS and Venimic LLC. The company has 4 employees (2026). In 2025, the company reported revenue of DKK 1,026,737 and a net result of DKK -1,626,789. Equity in the 2025 report amounted to DKK -1,570,789.
Selskabets formål er at udføre forskning, udvikling, produktion og handel med lægemidler, samt at udøve enhver aktivitet, der har direkte eller indirekte forbindelse hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202529/01/2025 – 31/12/2025 | 1M | -1.6M | 2.5M | -1.6M | - |
Compared to 1.037 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of Akasi Pharma ApS is 45364577.
Akasi Pharma ApS is owned by Walden Holding ApS, Sophie Holding ApS and Venimic LLC.
The management of Akasi Pharma ApS consists of Helena Safavi-Hemami and Walden Emil Bjørn-Yoshimoto.
In 2025, Akasi Pharma ApS reported revenue of DKK 1,026,737.
Akasi Pharma ApS had 4 employees in 2026 according to the Danish CVR register.
Akasi Pharma ApS was founded on 29 January 2025.
Claim this page to add your logo and social links. Free to get started.
Akasi Pharma ApS has published its annual report for 2025. Revenue came to DKK 1,026,737, and the net result was DKK -1,626,789.
As of October 17, 2025, Sophie Holding ApS is registered as an owner of Akasi Pharma ApS with an ownership share of 10%.
As of October 17, 2025, is registered as an owner of Akasi Pharma ApS with an ownership share of 25%.
As of January 29, 2025, Walden Emil Bjørn-Yoshimoto is registered as director of Akasi Pharma ApS.
As of January 29, 2025, Helena Safavi-Hemami is registered as director of Akasi Pharma ApS.
As of January 29, 2025, Walden Holding ApS is registered as an owner of Akasi Pharma ApS with an ownership share of 50%.
Akasi Pharma ApS was founded on January 29, 2025.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Companies in the same industry and area
CVR 36465972
CVR 45436497
CVR 46059220
CVR 41978074
CVR 46543912
